COVID-19 Variant Outbreak Spreads Rapidly in African Country

BA.3.2 'Cicada' COVID-19 variant detected in 23+ countries spreads globally from South African origin.

Objective Facts

The BA.3.2 variant was first identified in South Africa on November 22, 2024. Detections began increasing in September 2025, with the variant reported in 23 countries as of February 11, 2026. BA.3.2 has approximately 70–75 substitutions and deletions in the spike protein gene sequence relative to current vaccine targets JN.1 and LP.8.1. Despite recent detections in the United States, BA.3.2 is considered to pose a 'low additional public health risk', with early evidence suggesting this Omicron offshoot is not currently driving large waves of infection or more severe disease. The 2025-2026 COVID vaccines, which target the JN.1 lineage, are effective at protecting against severe disease from current strains, though in lab studies these vaccines were less effective against BA.3.2.

Deep Dive

BA.3.2 was first identified in South Africa in November 2024, but genetic analysis suggests it may have emerged sometime between December 2023 and July 2024, before being detected through surveillance. Researchers believe this points towards a 'saltation event': a sudden evolutionary leap in which the virus accumulates many mutations at once, rather than gradually, thought to occur during prolonged infections, where the virus has time to adapt under pressure from the immune system. As of April 2026, BA.3.2 has been detected in 23 countries with the highest concentration of cases in Australia at 13% of sequences, followed by South Africa at more than 10%, Germany at 10%, and Ireland at 7%. While scientists are keeping a close eye on the BA.3.2 variant, nicknamed 'Cicada', early evidence suggests this Omicron offshoot is not currently driving large waves of infection or more severe disease, with overall available evidence suggesting that BA.3.2 poses low additional public health risk compared with other circulating Omicron descendent lineages. In lab studies, current vaccines were less effective against BA.3.2, but more research is needed according to the CDC, though it's not completely clear how effective the current vaccine will be and it likely still has some effectiveness. There are no signs that the variant will be more severe or contagious than previous versions. Due to limited genomic detection and surveillance capacities in many countries worldwide, recorded detections likely underrepresent the extent of the spread of the new strain, with the CDC highlighting the need for ongoing genomic surveillance strategies and observational assessments of vaccine effectiveness. BA.3.2 mutations in the spike protein have the potential to reduce protection from a previous infection or vaccination, with continued genomic surveillance needed to track SARS-CoV-2 evolution and determine its potential effect on public health.

Regional Perspective

Regional detection patterns show BA.3.2 concentrated highest in Australia at 13% of sequences, followed by South Africa at more than 10%, and Germany at 10%. The African Union Assembly has commended the Africa CDC for strengthening continental leadership and surveillance capacity, increasing the internally managed grant portfolio from USD 52 million in 2022 to USD 462 million in 2025, reflecting sustained investments in surveillance and genomic sequencing that contributed to a reduction in disease outbreaks in 2025 compared to preceding three years. African analysis emphasizes data sovereignty concerns, with regional commentary stressing that health data derived from surveillance and pathogen processing must be securely managed and accountable to African institutions rather than foreign entities, noting that recent agreements with the US have brought this issue to the fore as some were asking African countries to sign away their health data or prodigally release their precious pathogens in exchange for donor funding. African scientists and genomic surveillance leaders indicate that sequencing laboratories are struggling with reagent shortages and the paucity of scientists with necessary expertise, with ever-present funding issues and reliance on external funders with their own agendas, and budgets under pressure particularly outside South Africa.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

COVID-19 Variant Outbreak Spreads Rapidly in African Country

BA.3.2 'Cicada' COVID-19 variant detected in 23+ countries spreads globally from South African origin.

May 31, 2026
COVID-19 Variant Outbreak Spreads Rapidly in African CountryVia Wikimedia (contextual reference image) · Subscribe to support objective journalism and fund real-time news imagery
What's Going On

The BA.3.2 variant was first identified in South Africa on November 22, 2024. Detections began increasing in September 2025, with the variant reported in 23 countries as of February 11, 2026. BA.3.2 has approximately 70–75 substitutions and deletions in the spike protein gene sequence relative to current vaccine targets JN.1 and LP.8.1. Despite recent detections in the United States, BA.3.2 is considered to pose a 'low additional public health risk', with early evidence suggesting this Omicron offshoot is not currently driving large waves of infection or more severe disease. The 2025-2026 COVID vaccines, which target the JN.1 lineage, are effective at protecting against severe disease from current strains, though in lab studies these vaccines were less effective against BA.3.2.

Left says: Insufficient left-leaning commentary found on this specific story to provide analysis.
Right says: Insufficient right-leaning commentary found on this specific story to provide analysis.
Region says: African Union leadership commended Africa CDC for strengthening surveillance and genomic sequencing capacity, increasing funding from USD 52 million in 2022 to USD 462 million in 2025, though African voices stress concerns about data sovereignty, noting that some international agreements have required African countries to sign away health data or release pathogens in exchange for donor funding.
Objective Deep Dive

BA.3.2 was first identified in South Africa in November 2024, but genetic analysis suggests it may have emerged sometime between December 2023 and July 2024, before being detected through surveillance. Researchers believe this points towards a 'saltation event': a sudden evolutionary leap in which the virus accumulates many mutations at once, rather than gradually, thought to occur during prolonged infections, where the virus has time to adapt under pressure from the immune system. As of April 2026, BA.3.2 has been detected in 23 countries with the highest concentration of cases in Australia at 13% of sequences, followed by South Africa at more than 10%, Germany at 10%, and Ireland at 7%.

While scientists are keeping a close eye on the BA.3.2 variant, nicknamed 'Cicada', early evidence suggests this Omicron offshoot is not currently driving large waves of infection or more severe disease, with overall available evidence suggesting that BA.3.2 poses low additional public health risk compared with other circulating Omicron descendent lineages. In lab studies, current vaccines were less effective against BA.3.2, but more research is needed according to the CDC, though it's not completely clear how effective the current vaccine will be and it likely still has some effectiveness. There are no signs that the variant will be more severe or contagious than previous versions.

Due to limited genomic detection and surveillance capacities in many countries worldwide, recorded detections likely underrepresent the extent of the spread of the new strain, with the CDC highlighting the need for ongoing genomic surveillance strategies and observational assessments of vaccine effectiveness. BA.3.2 mutations in the spike protein have the potential to reduce protection from a previous infection or vaccination, with continued genomic surveillance needed to track SARS-CoV-2 evolution and determine its potential effect on public health.